Clinical trial · no report yet · Phase 2
Hypo-FLAME
Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer
- NCT02853110 ↗
- Completed
- UMC Utrecht
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| Podcasts | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer (Hypo-FLAME)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer Adenocarcinoma
- Interventions
- Hypo-FLAME study
- Arms
- Hypo-FLAME · Experimental
- Enrollment
- 100
- Primary outcomes
- Acute toxicity
- Sponsor
- UMC Utrecht with The Netherlands Cancer Institute, Universitaire Ziekenhuizen KU Leuven, Radboud University Medical Center
- Start
- Apr 2016
- Primary completion
- Nov 1, 2018
- Results posted
- No
- Registry record
- NCT02853110 · updated Dec 20, 2018
Publications
linked from the registry- Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, De Boer H, Smeenk RJ, Kunze-Busch M, Monninkhof EM, De Roover R, Isebaert S, Kerkmeijer LGW. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024 Dec;201:110568. doi: 10.1016/j.radonc.2024.110568. Epub 2024 Oct 2. PubMed 39362607
- Goodman CD, Fakir H, Pautler S, Chin J, Bauman GS. Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. Adv Radiat Oncol. 2019 Sep 27;5(2):212-220. doi: 10.1016/j.adro.2019.09.004. eCollection 2020 Mar-Apr. PubMed 32280821
- Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, Groen VH, Monninkhof EM, Smeenk RJ, Kunze-Busch M, De Roover R, Depuydt T, Isebaert S, Kerkmeijer LGW. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020 Jun;147:92-98. doi: 10.1016/j.radonc.2020.03.015. Epub 2020 Apr 1. PubMed 32247206